Omnicell Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Omnicell (OMCL) Tops Q2 EPS by 14c, Revenues Beat; Offers 3Q EPS Outlook Below Consensus, 3Q Revenue Mid-Point Guidance Below Consensus
July 28, 2020 4:04 PM EDTOmnicell (NASDAQ: OMCL) reported Q2 EPS of $0.37, $0.14 better than the analyst estimate of $0.23. Revenue for the quarter came in at $199.6 million versus the consensus estimate of $182.42 million.
GAAP revenues of $199.6 million and net loss per diluted share of $0.10Non-GAAP revenues $199.6 million and net income per diluted share of $0.37Omnicells Response to Coronavirus (COVID-19)
Keeping in mind our role in the healthcare industry, we are continuing to closely monitor the COVID-19 pandemic. Our top priorities remain protecting the health and well-being of our customers, their patients, and our... More
